Schrödinger, Bayer collaborate to co-develop de novo design technology to accelerate drug discovery

This article was originally published here

The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates.

The post Schrödinger, Bayer collaborate to co-develop de novo design technology to accelerate drug discovery appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply